Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Total Liabilities (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Total Liabilities readings, the most recent being $24.2 million for Q4 2024.

  • On a quarterly basis, Total Liabilities rose 34.65% to $24.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $24.2 million, a 34.65% increase, with the full-year FY2024 number at $24.2 million, up 34.65% from a year prior.
  • Total Liabilities hit $24.2 million in Q4 2024 for Unicycive Therapeutics, up from $10.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $30.7 million in Q1 2024 to a low of $2.3 million in Q4 2021.
  • Median Total Liabilities over the past 4 years was $13.4 million (2024), compared with a mean of $12.5 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 563.16% in 2023 and later crashed 33.01% in 2024.
  • Unicycive Therapeutics' Total Liabilities stood at $2.3 million in 2021, then skyrocketed by 45.31% to $3.3 million in 2022, then surged by 448.11% to $18.0 million in 2023, then surged by 34.65% to $24.2 million in 2024.
  • The last three reported values for Total Liabilities were $24.2 million (Q4 2024), $10.7 million (Q3 2024), and $13.4 million (Q2 2024) per Business Quant data.